Targinta,Xintelassubsidiary with a focus on oncology, has initiated collaboration with Memorial Sloan Kettering Cancer Center(MSK) Therapeutics Accelerator for clinical development of integrin α10β1-targeted antibodies against aggressive sarcoma. Within the agreement, Targinta is responsible for producing the antibodies TARG9and TARG10while MSK is leading upcoming phase I/IIa studies. Targinta's portion of the collaboration will be financed through a directed new share issue to new investors directly in Targinta. Integrin α10β1 is expressed in 30-50 percent of aggressive sarcoma types with poor prognosis.
|
Published October 7, 2025
Xintela's subsidiary initiates collaboration with Memorial Sloan Kettering
Text:
News Desk [email protected]
Notes
OssDsign signs agreement in the western US
Annexin doses first patients in phase IIa study
Boule Diagnostics CEO leaves the company
Flerie divests Limited Partnership segment
Cantargia reports survival results from TRIFOUR
Guard Therapeutics explores strategic options
Thor Medical signs supply agreement with RadioMedix
NEWSLETTER
Today's news roundup
The news sweep Friday 05 December
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Global Forum 2026
This May, our premier event returns, dramatically expanded yet carefully curated to ensure a welcoming and high-value experience. We ha...
Investing in Life Science
Set in vibrant Stockholm, the Swedish finance capital, this boutique investor event connects regional life science leaders looking for strategic...
Recommended
BiBBInstruments validates clinical need during US tour
Sunstone sounds the alarm: “Danish startups are running on fumes”
Sprint Bioscience: "We have shown it is possible to make early deals"
How to take medtech to market – tips from those who have succeeded
Flerie seeks to merge with Lipum – creating a private platform for the next development phase of SOL-116
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account